Bereiche | Tage | Auswahl | Suche | Aktualisierungen | Downloads | Hilfe
MS: Fachverband Massenspektrometrie
MS 9: Resonance Ionization Mass Spectrometry
MS 9.7: Vortrag
Donnerstag, 14. März 2019, 15:45–16:00, U A-Esch 2
MELISSA at CERN-MEDICIS: current status and recent results — •Vadim Gadelshin1, Vincent Barozier2, Roberto Formento Cavaier3,4,5, Valentin Fedosseev2, Ferid Haddad3,4, Bruce Marsh2, Thierry Stora2, Dominik Studer1, Felix Weber1, and Klaus Wendt1 — 1Johannes Gutenberg-Universität Mainz — 2CERN, Switzerland — 3GIP ARRONAX, France — 4SUBATECH, Nantes University, France — 5Advanced Accelerator Applications, Novartis Group, France
2018 was the first operational year of the CERN-MEDICIS facility, which aims for a regular production of 500 MBq batches of innovative medical radionuclides. During this year, several important milestones were achieved: the production of a high specific activity of Er-169, the delivery of Tb-149 and Tb-155 for medical R&D to members of the MEDICIS Collaboration, successful tests of new types of highly efficient production targets, and Machine Development runs, preparing future upgrades.
The first year of the operation confirmed the necessity to optimize the output to reach a high separation efficiency and a best possible purity. As an effect, the construction and installation of the MEDICIS Laser Ion Source MELISSA were strongly boosted.
In the talk, the current status of the MELISSA is introduced. An overview on the accomplished work as well as the ongoing and planned activities is presented. Key benefits of the laser ion source are highlighted, possible modifications for the design of the target ion source unit are discussed. (EU H2020 grant #642889 MEDICIS-PROMED)